P53 Arg72Pro polymorphism and bladder cancer risk - meta-analysis evidence for a link in Asians but not caucasians

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2349-2354

  Xu, Ting ^a   Xu, Zi Cheng ^a   Zou, Qin ^a   Yu, Bin ^a   Huang, Xin En ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bladder carcinoma; Meta analysis; P53 codon 72; Polymorphism; Susceptibility

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ARTICLE; ASIAN; BLADDER TUMOR; CASE CONTROL STUDY; CAUCASIAN; ETHNOLOGY; GENETIC POLYMORPHISM; GENETICS; HUMAN; META ANALYSIS; PROGNOSIS; RISK FACTOR;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84872684740     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2349     Document Type: Article

References (47)

1. Biro E, Kalina I, Salagovic J, et al (2000). p53 single nucleotide polymorphisms and bladder cancer. Neoplasma, 47, 303-6.
2. Bryan RT, Hussain SA, James ND, et al (2005). Molecular pathways in bladder cancer: part 2. BJU Int, 95, 491-6.
3. Chang CC, Hsieh YY, Tsai FJ, et al (2002). The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil Steril, 77, 43-5.
4. Chen WC, Tsai FJ, Wu JY, et al (2000). Distributions of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor. Urol Res, 28, 293-6.
5. Chung CJ, Huang CJ, Pu YS, et al (2008). Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma. Toxicol Appl Pharmacol, 232, 203-9.
6. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
7. Dumont P, Leu JI, Della Pietra AC, 3rd, et al (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet, 33, 357-65.
8. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
9. Gao LL, Huang XE, Zhang Q, et al (2011). 14.A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
10. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pacific J Cancer Prev, (in press).
11. Herr HW, Sogani PC (2001). Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol, 166, 1296-9.
12. Horikawa Y, Nadaoka J, Saito M, et al (2008). Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep, 20, 49-55.
13. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a Phase II trial. Asian Pacific J Cancer Prev, 12, 2797-800.
14. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
15. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 11, 1059-62.
16. Kaufman DS, Shipley WU, Feldman AS (2009). Bladder cancer. Lancet, 374, 239-49.
17. Klug SJ, Ressing M, Koenig J, et al (2009). TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol, 10, 772-84.
18. Kuroda Y, Tsukino H, Nakao H, et al (2003). p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett, 189, 77-83.
19. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell, 88, 323-31.
20. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin® administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
21. Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pacific J Cancer Prev, 12, 487-90.
22. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pacific J Cancer Prev, 13, 301-4.
23. Lin HY, Yang MC, Huang CH, et al (2011) Polymorphisms of TP53 are markers of bladder cancer vulnerability and prognosis. Urol Oncol. 2011 Dec 16.
24. Li Y, Yan PW, Huang XE, et al (2011). MDR1 Gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 12, 2405-9.
25. Mabrouk I, Baccouche S, El-Abed R, et al (2003). No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci, 1010, 764-70.
26. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
27. Meek DW (2004). The p53 response to DNA damage. DNA Repair (Amst), 3, 1049-56.
28. Pandith AA, Shah ZA, Khan NP, et al (2010). Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. Cancer Genet Cytogenet, 203, 263-8.
29. Sager R (1989). Tumor suppressor genes: the puzzle and the promise. Science, 246, 1406-12.
30. Santos LE, Guilhen AC, de Andrade RA, et al (2011). The role of TP53 PRO47SER and ARG72PRO single nucleotide polymorphisms in the susceptibility to bladder cancer. Urol Oncol, 29, 291-4.
31. Soulitzis N, Sourvinos G, Dokianakis DN, et al (2002). p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett, 179, 175-83.
32. Srivastava P, Jaiswal PK, Singh V, et al (2010). Role of p53 gene polymorphism and bladder cancer predisposition in northern India. Cancer Biomark, 8, 21-8.
33. Toruner GA, Ucar A, Tez M, et al (2001). P53 codon 72 polymorphism in bladder cancer-no evidence of association with increased risk or invasiveness. Urol Res, 29, 393-5.
34. Williams SG, Stein JP (2004). Molecular pathways in bladder cancer. Urol Res, 32, 373-85.
35. Wu WJ, Kakehi Y, Habuchi T, et al (1995). Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res, 86, 730-6.
36. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
37. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
38. Xu H, el-Gewely MR (2001). P53-responsive genes and the potential for cancer diagnostics and therapeutics development. Biotechnol Annu Rev, 7, 131-64.
39. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
40. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
41. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
42. Ye Y, Yang H, Grossman HB, et al (2008). Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer, 112, 2467-74.
43. Yu DS, Huang XE, Zhou JN, et al (2012). A Comparative Study on the Value of Anal Preserving Surgery for Aged People with Low Rectal Carcinoma in Jiangsu, China. Asian Pacific J Cancer Prev, (in press).
44. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
45. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
46. Zhang R, Chen W, Zhang W, et al (2011). Genetic polymorphisms of p53 codon 72 and bladder cancer susceptibility: a hospital-based case-control study. Genet Test Mol Biomarkers, 15, 337-41.
47. Zhang XZ, Huang XE, Xu YL, et al (2012). A Phase II study on voriconazole in treating Chinese patients with malignant hematological disorder and invasive aspergillosis. Asian Pacific J Cancer Prev, (in press).